Table 1.

Lipophagy and lipophagy-related metabolic disorders: Identified proteins and the possible therapeutic

Metabolic disorder	Lipophagy status	Key protein	Possible therapeutic	Reference
Obesity	Decrease	Bif-1, CaMKIV, SIRT3, etc.	Upregulation	(Liu et al., 2016; 2020; Xu et al., 2013; Zhang et al., 2020)
Diabetes mellitus	Decrease	FGF21, etc.	Upregulation	(Byun et al., 2020; Kim et al., 2013)
Alcholic fatty liver disease	Decrease	AKT, FXR, Nrf2, mTOR, Rab7, etc.	Upregulation	(Schulze et al., 2017b; Wu et al., 2014; Zhang et al., 2018b; Zhao et al., 2018)
Non-alcoholic fatty liver disease	Decrease	AMPK, GNMT, FGF21, IRGM, Rubicon, SOD1, SREBP-2, etc.	Upregulation	(Deng et al., 2017; Levine and Kroemer, 2019; Kurahashi et al., 2015; Lin et al., 2016; Smith et al., 2016; Tanaka et al., 2016; Zhu et al., 2016; Zubiete-Franco et al., 2016)
Liver fibrosis	Increase	Perilipin 1, PNPLA3, Rab18, Rab25, etc.	Downregulation	(Bruschi et al., 2017; Miyamae et al., 2016; O'Mahony et al., 2015; Pirazzi et al., 2014; Zhang et al., 2017)